Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.79% 0.05% 43.33M 5695.23
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.93% 53.00% -1.019M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Loncar Investments
Prospectus Benchmark Index
Loncar Cancer Immunotherapy TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Austin Wen 2.67 yrs
Rafael Zayas 1.20 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 34
-1.019M
-4.532B Category Low
6.619B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of August 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of September 27, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
-25.62%
13.57%
-20.62%
24.19%
36.52%
-1.25%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
16.31%
25.42%
0.27%
-5.21%
21.82%
-1.33%
22.26%
28.00%
13.95%
29.45%
1.64%
-23.20%
12.05%
-15.32%
25.62%
14.68%
-6.11%
--
--
-1.39%
21.78%
2.10%
21.20%
19.20%
14.60%
--
--
--
19.40%
-9.50%
22.13%
11.70%
0.67%
As of September 27, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (9-28-21) 0.93%
30-Day SEC Yield (8-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of September 24, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of September 24, 2021

Asset Allocation

As of September 24, 2021.
Type % Net % Long % Short
Cash 0.02% Upgrade Upgrade
Stock 99.98% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Trillium Therapeutics Inc 6.08% 22.57 0.71%
Arcus Biosciences Inc 4.86% 36.14 -4.07%
Instil Bio Inc 4.64% 23.15 -0.56%
ALX Oncology Holdings Inc Ordinary Shares 4.13% 74.81 -2.68%
Regeneron Pharmaceuticals Inc 4.04% 604.87 -2.29%
Atara Biotherapeutics Inc 3.98% 17.39 -0.46%
Legend Biotech Corp ADR 3.86% 46.67 -0.68%
Iovance Biotherapeutics Inc 3.63% 24.62 -2.67%
BeiGene Ltd ADR 3.62% 364.51 -3.36%
Nektar Therapeutics 3.49% 18.41 -2.28%

Basic Info

Investment Strategy
The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Loncar Investments
Prospectus Benchmark Index
Loncar Cancer Immunotherapy TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Austin Wen 2.67 yrs
Rafael Zayas 1.20 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (9-28-21) 0.93%
30-Day SEC Yield (8-31-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of September 24, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of September 24, 2021

Fund Details

Key Dates
Inception Date 10/13/2015
Last Annual Report Date 8/31/2020
Last Prospectus Date 12/31/2020
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No